Imperial College London
Alternate

Emeritus ProfessorPetrosNihoyannopoulos

Faculty of Medicine, National Heart & Lung Institute

Emeritus Professor
 
 
 
//

Contact

 

+44 (0)20 3313 8156p.nihoyannopoulos

 
 
//

Location

 

Hammersmith HospitalHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Katsi:2017:10.1080/03007995.2017.1330257,
author = {Katsi, V and Georgiopoulos, G and Marketou, M and Oikonomou, D and Parthenakis, F and Makris, T and Nihoyannopoulos, P and Vardas, P and Tousoulis, D},
doi = {10.1080/03007995.2017.1330257},
journal = {Curr Med Res Opin},
pages = {1497--1504},
title = {Atrial fibrillation in pregnancy: a growing challenge.},
url = {http://dx.doi.org/10.1080/03007995.2017.1330257},
volume = {33},
year = {2017}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: Atrial fibrillation (AF) constitutes a relatively infrequent pregnancy complication, which may be a therapeutic Gordian knot. Indeed, sparse data exist regarding the prevalence, prognosis, and management of AF during pregnancy. In general, AF occurs as a benign, self-limited arrhythmia, but occasionally may have severe hemodynamic consequences in pregnant patients suffering from heart failure, congenital heart disease, or other comorbidities. Extra-cardiac causes of AF should always be meticulously excluded. REVIEW: Treatment decisions are difficult, since medications may cross the placental barrier and potentially affect fetal growth and organogenesis, or even result in fetal bradyarrhythmias. Treatment goals are not differentiated in comparison to those regarding AF occurring in the general population. Still, while maternal treatment is prioritized, issues regarding fetal health must deliberately be considered. Consequently, hemodynamic instability is to be promptly treated with synchronized electrical cardioversion. In contrast, in stable patients, pharmacologic cardioversion, under appropriate antithrombotic regimen, should be attempted. Selection of appropriate antithrombotic therapy, including novel oral anticoagulants, imposes further difficulties on therapeutic decision-making. Further clinical trials are warranted in order to assess the pathophysiology and prognosis of AF in pregnancy and ameliorate the evidence-based therapeutic strategy in this specific group of the population.
AU  - Katsi,V
AU  - Georgiopoulos,G
AU  - Marketou,M
AU  - Oikonomou,D
AU  - Parthenakis,F
AU  - Makris,T
AU  - Nihoyannopoulos,P
AU  - Vardas,P
AU  - Tousoulis,D
DO  - 10.1080/03007995.2017.1330257
EP  - 1504
PY  - 2017///
SP  - 1497
TI  - Atrial fibrillation in pregnancy: a growing challenge.
T2  - Curr Med Res Opin
UR  - http://dx.doi.org/10.1080/03007995.2017.1330257
UR  - https://www.ncbi.nlm.nih.gov/pubmed/28498066
VL  - 33
ER  -
Download